Previous 10 | Next 10 |
CINCINNATI, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021. Jack Kenny, Chief Executive Officer, and...
Meridian could expand its testing supply windfall in 2021, as the world grapples with containing mutations of the COVID-19 virus. Balance sheet safety, profit margins, revenue growth, and current valuations are better than industry average. A large short interest position and a nu...
Gainers: [[VIVO]] +6%. [[ABUS]] +4.6%. [[AY]] +4.2%. [[EBON]] +3.5%. [[TSE]] +3.4%.Losers: [[ACLS]] -14%. [[DOGZ]] -8.5%. [[HX]] -7.8%. [[FIXX]] -5.9%. [[JRJC]] -2.1%. For further details see: AY, ABUS, ACLS and FIXX among after-hours movers
Meridian Bioscience ([[VIVO]] -2.0%) reported preliminary net revenue for Q1 of $92M compared to $47.4M a year ago, reflecting an increase of approximately 94% and better than consensus of $81.4M.Sees Life Science segment revenue of ~$62M, exceeding expectations due to the high demand fo...
CINCINNATI, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced preliminary financial results for the first quarter of fiscal 2021. Preliminary First Quarter Fiscal 2021 Res...
CINCINNATI, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference. Jack Kenny, Chief Executive Officer,...
The seasonally-strongest baskets include gold and technology. The top stocks in each major sector right now. The best sectors include consumer goods, industrial goods, and financials. For further details see: The Top Stocks To Buy In The New Year
Meridian Bioscience ([[VIVO]] -3.3%) has been awarded funding of ~$1M by the National Institute of Health ((NIH)) Rapid Acceleration of Diagnostics initiative, to accelerate the launch of the company’s SARS-CoV-2 molecular diagnostic test on the Revogene platform.Recently,...
CINCINNATI, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has been awarded funding in the amount of approximately $1M by the National Institute of Health (NIH) Ra...
Meridian Bioscience ([[VIVO]] -1.0%) has submitted its application for Emergency Use Authorization ((EUA)) to the FDA for its SARS-CoV-2 molecular diagnostic test on the Revogene platform.The molecular diagnostic test is for the qualitative detection of the SARS-CoV-2 virus, with results...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...